Dual inhibition of TGF‐β and PD‐L1: a novel approach to cancer treatment-Reference-Cited by-同舟云学术

Dual inhibition of TGF‐β and PD‐L1: a novel approach to cancer treatment

Published:2022-01-04 Issue: Volume: Page:
ISSN:1574-7891
Container-title:Molecular Oncology
language:en
Short-container-title:Molecular Oncology

Author:

Gulley James L.¹^ORCID,Schlom Jeffrey²,Barcellos‐Hoff Mary Helen³,Wang Xiao‐Jing⁴,Seoane Joan⁵,Audhuy Francois⁶,Lan Yan⁶,Dussault Isabelle⁶,Moustakas Aristidis⁷^ORCID

Affiliation:

1. Genitourinary Malignancies Branch Center for Cancer Research National Cancer Institute Bethesda MD USA

2. Laboratory of Tumor Immunology and Biology Center for Cancer Research National Cancer Institute Bethesda MD USA

3. Department of Radiation Oncology University of California San Francisco San Francisco CA USA

4. Department of Pathology University of Colorado Aurora CO USA

5. ICREA Vall D’Hebron Institute of Oncology CIBERONC Universitat Autonoma de Barcelona Barcelona Spain

6. EMD Serono Billerica MA USA

7. Department of Medical Biochemistry and Microbiology Science for Life Laboratory Uppsala University Uppsala Sweden

Funder

Merck KGaA

GlaxoSmithKline

National Cancer Institute

National Institutes of Health

EMD Serono

Publisher

Wiley

Subject

Cancer Research,Genetics,Molecular Medicine,General Medicine,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/1878-0261.13146

Reference138 articles.

1. Clinical development of therapies targeting TGFβ: current knowledge and future perspectives

2. Signaling Receptors for TGF-β Family Members

3. Transforming Growth Factor-β Signaling in Immunity and Cancer

4. Therapeutic targeting of TGF-β in cancer: hacking a master switch of immune suppression

5. Contextual Regulation of Inflammation: A Duet by Transforming Growth Factor-β and Interleukin-10

Cited by 77 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Regulatory T cells: masterminds of immune equilibrium and future therapeutic innovations;Frontiers in Immunology;2024-09-03

2. Evolving treatment landscape in thymic epithelial tumors: From mechanism to therapy;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-09

3. PF-06952229, a selective TGF-β-R1 inhibitor: preclinical development and a first-in-human, phase I, dose-escalation study in advanced solid tumors;ESMO Open;2024-09

4. Recent advances and molecular mechanisms of TGF-β signaling in colorectal cancer, with focus on bioactive compounds targeting;Biomedicine & Pharmacotherapy;2024-08

5. Insights into the mechanisms, regulation, and therapeutic implications of extracellular matrix stiffness in cancer;Bioengineering & Translational Medicine;2024-07-31